D100 LIGELIZUMAB ACHIEVES FAST CONTROL OF SYMPTOMS IN MORE PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA VERSUS OMALIZUMAB

T. Severin,W. Soong,M. Maurer,A. Giménez-Arnau,M. Hide, J. Bernstein,E. Hua,A. Barve,R. Janocha

Annals of Allergy, Asthma & Immunology（2020）

引用 0|浏览19

暂无评分

摘要

In a Phase 2b study, ligelizumab demonstrated excellent symptom control in patients with moderate-to-severe chronic spontaneous urticaria (CSU). Here, we analyzed the time to response of ligelizumab 72mg and 240mg versus omalizumab 300mg.

查看译文

关键词

Omalizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要